

Alan J Thompson

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4470751/publications.pdf>

Version: 2024-02-01

302
papers

54,467
citations

4103

90
h-index

1446

226
g-index

320
all docs

320
docs citations

320
times ranked

33960
citing authors

#	ARTICLE	IF	CITATIONS
1	Spatial patterns of brain lesions assessed through covariance estimations of lesional voxels in multiple Sclerosis: The SPACE-MS technique. <i>NeuroImage: Clinical</i> , 2022, 33, 102904.	1.4	5
2	Charting a global research strategy for progressive MS—An international progressive MS Alliance proposal. <i>Multiple Sclerosis Journal</i> , 2022, 28, 16-28.	1.4	5
3	Simultaneous assessment of regional distributions of atrophy across the neuraxis in MS patients. <i>NeuroImage: Clinical</i> , 2022, 34, 102985.	1.4	5
4	Two years of COVID-19 in the MS community: What have we learnt so far?. <i>Multiple Sclerosis Journal</i> , 2022, 28, 1005-1008.	1.4	3
5	Primary progressive multiple sclerosis presenting under the age of 18 years: Fact or fiction?. <i>Multiple Sclerosis Journal</i> , 2021, 27, 309-314.	1.4	5
6	Ongoing microstructural changes in the cervical cord underpin disability progression in early primary progressive multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2021, 27, 28-38.	1.4	11
7	Brenda Banwell. , 2021, , 609-611.		0
8	Identifying multiple sclerosis subtypes using unsupervised machine learning and MRI data. <i>Nature Communications</i> , 2021, 12, 2078.	5.8	112
9	Cortical involvement determines impairment 30 years after a clinically isolated syndrome. <i>Brain</i> , 2021, 144, 1384-1395.	3.7	24
10	Longitudinal changes of spinal cord grey and white matter following spinal cord injury. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2021, 92, 1222-1230.	0.9	20
11	Paradigm shifts: Early initiation of high-efficacy disease-modifying treatment in multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2021, 27, 1473-1476.	1.4	21
12	Clinical relevance of cortical network dynamics in early primary progressive MS. <i>Multiple Sclerosis Journal</i> , 2020, 26, 442-456.	1.4	14
13	Improved performance of the 2017 McDonald criteria for diagnosis of multiple sclerosis in children in a real-life cohort. <i>Multiple Sclerosis Journal</i> , 2020, 26, 1372-1380.	1.4	28
14	Reduced neurite density in the brain and cervical spinal cord in relapsingâ€“remitting multiple sclerosis: A NODDI study. <i>Multiple Sclerosis Journal</i> , 2020, 26, 1647-1657.	1.4	48
15	A 30â€“Year Clinical and Magnetic Resonance Imaging Observational Study of Multiple Sclerosis and Clinically Isolated Syndromes. <i>Annals of Neurology</i> , 2020, 87, 63-74.	2.8	67
16	Towards treating progressive multiple sclerosis. <i>Nature Reviews Neurology</i> , 2020, 16, 589-590.	4.9	15
17	Atlas of MS 2020: Informing global policy change. <i>Multiple Sclerosis Journal</i> , 2020, 26, 1807-1808.	1.4	18
18	Pathologic correlates of the magnetization transfer ratio in multiple sclerosis. <i>Neurology</i> , 2020, 95, e2965-e2976.	1.5	28

#	ARTICLE	IF	CITATIONS
19	The 2013 clinical course descriptors for multiple sclerosis. <i>Neurology</i> , 2020, 94, 1088-1092.	1.5	73
20	Aggressive multiple sclerosis (2): Treatment. <i>Multiple Sclerosis Journal</i> , 2020, 26, 1045-1063.	1.4	21
21	Aggressive multiple sclerosis (1): Towards a definition of the phenotype. <i>Multiple Sclerosis Journal</i> , 2020, 26, 1031-1044.	1.4	39
22	Disrupted principal network organisation in multiple sclerosis relates to disability. <i>Scientific Reports</i> , 2020, 10, 3620.	1.6	2
23	MRI in traumatic spinal cord injury: from clinical assessment to neuroimaging biomarkers. <i>Lancet Neurology</i> , The, 2019, 18, 1123-1135.	4.9	125
24	Traumatic and nontraumatic spinal cord injury: pathological insights from neuroimaging. <i>Nature Reviews Neurology</i> , 2019, 15, 718-731.	4.9	125
25	Spinal cord involvement in multiple sclerosis and neuromyelitis optica spectrum disorders. <i>Lancet Neurology</i> , The, 2019, 18, 185-197.	4.9	110
26	Applying causal models to explore the mechanism of action of simvastatin in progressive multiple sclerosis. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2019, 116, 11020-11027.	3.3	28
27	MSJ 2019 - Editorial comment. <i>Multiple Sclerosis Journal</i> , 2019, 25, 4-5.	1.4	0
28	Structural network disruption markers explain disability in multiple sclerosis. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2019, 90, 219-226.	0.9	37
29	Progressive neurodegeneration following spinal cord injury. <i>Neurology</i> , 2018, 90, e1257-e1266.	1.5	97
30	Dorsal and ventral horn atrophy is associated with clinical outcome after spinal cord injury. <i>Neurology</i> , 2018, 90, e1510-e1522.	1.5	44
31	Time matters in multiple sclerosis: can early treatment and long-term follow-up ensure everyone benefits from the latest advances in multiple sclerosis?. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2018, 89, 844-850.	0.9	102
32	ECTRIMS/EAN Guideline on the pharmacological treatment of people with multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2018, 24, 96-120.	1.4	458
33	Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria. <i>Lancet Neurology</i> , The, 2018, 17, 162-173.	4.9	4,605
34	Assessing treatment outcomes in multiple sclerosis trials and in the clinical setting. <i>Nature Reviews Neurology</i> , 2018, 14, 75-93.	4.9	115
35	Unified understanding of MS course is required for drug development. <i>Nature Reviews Neurology</i> , 2018, 14, 191-192.	4.9	11
36	Deep gray matter volume loss drives disability worsening in multiple sclerosis. <i>Annals of Neurology</i> , 2018, 83, 210-222.	2.8	295

#	ARTICLE	IF	CITATIONS
37	Commentary on theECTRIMSâ€“EAN guideline for pharmacological treatment of multiple sclerosis. Therapeutic Advances in Neurological Disorders, 2018, 11, 175628641877037.	1.5	2
38	MSJ 2018â€“editorial comment. Multiple Sclerosis Journal, 2018, 24, 90-91.	1.4	1
39	Multiple sclerosis. Lancet, The, 2018, 391, 1622-1636.	6.3	1,204
40	Landscape of MS patient cohorts and registries: Recommendations for maximizing impact. Multiple Sclerosis Journal, 2018, 24, 579-586.	1.4	24
41	Spinal cord atrophy as a primary outcome measure in phase II trials of progressive multiple sclerosis. Multiple Sclerosis Journal, 2018, 24, 932-941.	1.4	37
42	Author response: Progressive neurodegeneration following spinal cord injury: Implications for clinical trials. Neurology, 2018, 91, 985-985.	1.5	7
43	2018 Editorsâ€™ commentary. Multiple Sclerosis Journal, 2018, 24, 1394-1395.	1.4	0
44	Quantitative MRI of rostral spinal cord and brain regions is predictive of functional recovery in acute spinal cord injury. NeuroImage: Clinical, 2018, 20, 556-563.	1.4	46
45	Progression of regional grey matter atrophy in multiple sclerosis. Brain, 2018, 141, 1665-1677.	3.7	269
46	Applying the 2017 McDonald diagnostic criteria for multiple sclerosis â€“ Authors' reply. Lancet Neurology, The, 2018, 17, 499-500.	4.9	35
47	New insights into the burden and costs of multiple sclerosis in Europe. Multiple Sclerosis Journal, 2017, 23, 1123-1136.	1.4	472
48	The measure tells the tale: Clinical outcome measures in multiple sclerosis. Multiple Sclerosis Journal, 2017, 23, 626-627.	1.4	5
49	Challenge of progressive multiple sclerosis therapy. Current Opinion in Neurology, 2017, 30, 237-240.	1.8	20
50	When are we going to take modifiable risk factors more seriously in multiple sclerosis?. Multiple Sclerosis Journal, 2017, 23, 494-495.	1.4	7
51	Multiple sclerosis: the upward trajectory continues. Lancet Neurology, The, 2017, 16, 10-12.	4.9	2
52	Advancing trial design in progressive multiple sclerosis. Multiple Sclerosis Journal, 2017, 23, 1571-1572.	1.4	5
53	Exercise in patients with multiple sclerosis. Lancet Neurology, The, 2017, 16, 848-856.	4.9	316
54	Editorial 2017. Multiple Sclerosis Journal, 2017, 23, 4-4.	1.4	0

#	ARTICLE	IF	CITATIONS
55	New insights into the burden and costs of multiple sclerosis in Europe: Results for the United Kingdom. <i>Multiple Sclerosis Journal</i> , 2017, 23, 204-216.	1.4	24
56	Progressive multiple sclerosis: prospects for disease therapy, repair, and restoration of function. <i>Lancet</i> , The, 2017, 389, 1357-1366.	6.3	235
57	Editorial. <i>Multiple Sclerosis Journal</i> , 2017, 23, 2-3.	1.4	6
58	Cell-based therapeutic strategies for multiple sclerosis. <i>Brain</i> , 2017, 140, 2776-2796.	3.7	139
59	Pharmacological management of spasticity in multiple sclerosis: Systematic review and consensus paper. <i>Multiple Sclerosis Journal</i> , 2016, 22, 1386-1396.	1.4	118
60	Voxel-based analysis of grey and white matter degeneration in cervical spondylotic myelopathy. <i>Scientific Reports</i> , 2016, 6, 24636.	1.6	52
61	Gray matter MRI differentiates neuromyelitis optica from multiple sclerosis using random forest. <i>Neurology</i> , 2016, 87, 2463-2470.	1.5	63
62	Editorial 2016. <i>Multiple Sclerosis Journal</i> , 2016, 22, 4-4.	1.4	0
63	Embodied neurology: an integrative framework for neurological disorders. <i>Brain</i> , 2016, 139, 1855-1861.	3.7	39
64	White matter tract abnormalities are associated with cognitive dysfunction in secondary progressive multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2016, 22, 1429-1437.	1.4	30
65	White and gray matter damage in primary progressive MS. <i>Neurology</i> , 2016, 86, 170-176.	1.5	34
66	The challenge of comorbidity in clinical trials for multiple sclerosis. <i>Neurology</i> , 2016, 86, 1437-1445.	1.5	48
67	Recommendations for observational studies of comorbidity in multiple sclerosis. <i>Neurology</i> , 2016, 86, 1446-1453.	1.5	64
68	Longitudinal evidence for anterograde trans-synaptic degeneration after optic neuritis. <i>Brain</i> , 2016, 139, 816-828.	3.7	67
69	DIR-visible grey matter lesions and atrophy in multiple sclerosis: partners in crime?. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2016, 87, 461-467.	0.9	38
70	Tracking sensory system atrophy and outcome prediction in spinal cord injury. <i>Annals of Neurology</i> , 2015, 78, 751-761.	2.8	77
71	A Predictive Model for Corticosteroid Response in Individual Patients with MS Relapses. <i>PLoS ONE</i> , 2015, 10, e0120829.	1.1	6
72	Evidence for early neurodegeneration in the cervical cord of patients with primary progressive multiple sclerosis. <i>Brain</i> , 2015, 138, 1568-1582.	3.7	51

#	ARTICLE	IF	CITATIONS
73	Predicting outcome in clinically isolated syndrome using machine learning. <i>NeuroImage: Clinical</i> , 2015, 7, 281-287.	1.4	61
74	A much-needed focus on progression in multiple sclerosis. <i>Lancet Neurology</i> , The, 2015, 14, 133-135.	4.9	30
75	Reduced gamma-aminobutyric acid concentration is associated with physical disability in progressive multiple sclerosis. <i>Brain</i> , 2015, 138, 2584-2595.	3.7	95
76	Progressive MS: from pathophysiology to drug discovery. <i>Multiple Sclerosis Journal</i> , 2015, 21, 1376-1384.	1.4	35
77	Atlas of Multiple Sclerosis 2013: A growing global problem with widespread inequity. <i>Neurology</i> , 2014, 83, 1022-1024.	1.5	953
78	SPINAL CORD GLUTAMATE-GLUTAMINE IS ELEVATED IN MS RELAPSE. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2014, 85, e4.30-e4.	0.9	0
79	Memory in multiple sclerosis is linked to glutamate concentration in grey matter regions. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2014, 85, 833-839.	0.9	77
80	Spatial variability and changes of metabolite concentrations in the corticoâ€špinal tract in multiple sclerosis using coronal CSI. <i>Human Brain Mapping</i> , 2014, 35, 993-1003.	1.9	11
81	Temporal and spatial evolution of grey matter atrophy in primary progressive multiple sclerosis. <i>NeuroImage</i> , 2014, 86, 257-264.	2.1	44
82	A novel approach with â€œskeletonised MTRâ€•measures tractâ€šspecific microstructural changes in early primaryâ€šprogressive MS. <i>Human Brain Mapping</i> , 2014, 35, 723-733.	1.9	12
83	Control of spasticity in a multiple sclerosis model using central nervous systemâ€šexcluded CB ₁ cannabinoid receptor agonists. <i>FASEB Journal</i> , 2014, 28, 117-130.	0.2	32
84	Voxel-based cervical spinal cord mapping of diffusion abnormalities in MS-related myelitis. <i>Neurology</i> , 2014, 83, 1321-1325.	1.5	24
85	Symptomatic treatment and management of multiple sclerosis. <i>Handbook of Clinical Neurology</i> / Edited By P J Vinken and G W Bruyn, 2014, 122, 513-562.	1.0	49
86	HLA-DRB1*15 influences the development of brain tissue damage in early PPMS. <i>Neurology</i> , 2014, 83, 1712-1718.	1.5	18
87	Defining the clinical course of multiple sclerosis. <i>Neurology</i> , 2014, 83, 278-286.	1.5	2,344
88	Age Related Changes in Metabolite Concentrations in the Normal Spinal Cord. <i>PLoS ONE</i> , 2014, 9, e105774.	1.1	16
89	Corpus callosum damage predicts disability progression and cognitive dysfunction in primaryâ€šprogressive MS after five years. <i>Human Brain Mapping</i> , 2013, 34, 1163-1172.	1.9	45
90	Treatment of cognitive impairment in multiple sclerosis: position paper. <i>Journal of Neurology</i> , 2013, 260, 1452-1468.	1.8	189

#	ARTICLE	IF	CITATIONS
91	MRI investigation of the sensorimotor cortex and the corticospinal tract after acute spinal cord injury: a prospective longitudinal study. <i>Lancet Neurology</i> , The, 2013, 12, 873-881.	4.9	239
92	Low Myoâ€inositol indicating astrocytic damage in a case series of neuromyelitis optica. <i>Annals of Neurology</i> , 2013, 74, 301-305.	2.8	44
93	Metabolic Changes in the Spinal Cord After Brachial Plexus Root Re-implantation. <i>Neurorehabilitation and Neural Repair</i> , 2013, 27, 118-124.	1.4	18
94	Multiple Sclerosis International Federation: Stimulating international cooperation in research. <i>Neurology</i> , 2013, 81, 1793-1795.	1.5	3
95	Achieving valid patient-reported outcomes measurement: a lesson from fatigue in multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2013, 19, 1773-1783.	1.4	32
96	Tracking Changes following Spinal Cord Injury. <i>Neuroscientist</i> , 2013, 19, 116-128.	2.6	76
97	Removal of access to alemtuzumab for patients with aggressive multiple sclerosis. <i>BMJ</i> , The, 2013, 346, f275-f275.	3.0	2
98	Impact on Clinical and Cost Outcomes of a Centralized Approach to Acute Stroke Care in London: A Comparative Effectiveness Before and After Model. <i>PLoS ONE</i> , 2013, 8, e70420.	1.1	79
99	Axonal integrity predicts cortical reorganisation following cervical injury. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2012, 83, 629-637.	0.9	65
100	Setting a research agenda for progressive multiple sclerosis: The International Collaborative on Progressive MS. <i>Multiple Sclerosis Journal</i> , 2012, 18, 1534-1540.	1.4	116
101	Connecting to the future â€“ the promise of telecare. <i>Multiple Sclerosis Journal</i> , 2012, 18, 384-386.	1.4	5
102	Changes in Auditory Feedback Connections Determine the Severity of Speech Processing Deficits after Stroke. <i>Journal of Neuroscience</i> , 2012, 32, 4260-4270.	1.7	35
103	Brain lesion location and clinical status 20 years after a diagnosis of clinically isolated syndrome suggestive of multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2012, 18, 322-328.	1.4	33
104	What sample sizes for reliability and validity studies in neurology?. <i>Journal of Neurology</i> , 2012, 259, 2681-2694.	1.8	140
105	Muscle paresis and passive stiffness: Key determinants in limiting function in Hereditary and Sporadic Spastic Paraparesis. <i>Gait and Posture</i> , 2012, 35, 266-271.	0.6	46
106	Linking white matter tracts to associated cortical grey matter: A tract extension methodology. <i>NeuroImage</i> , 2012, 59, 3094-3102.	2.1	17
107	Neuroplasticity and functional recovery in multiple sclerosis. <i>Nature Reviews Neurology</i> , 2012, 8, 635-646.	4.9	128
108	Degeneration of the Injured Cervical Cord Is Associated with Remote Changes in Corticospinal Tract Integrity and Upper Limb Impairment. <i>PLoS ONE</i> , 2012, 7, e51729.	1.1	62

#	ARTICLE	IF	CITATIONS
109	Autologous mesenchymal stem cells for the treatment of secondary progressive multiple sclerosis: an open-label phase 2a proof-of-concept study. <i>Lancet Neurology</i> , The, 2012, 11, 150-156.	4.9	548
110	A comprehensive assessment of cerebellar damage in multiple sclerosis using diffusion tractography and volumetric analysis. <i>Multiple Sclerosis Journal</i> , 2011, 17, 1079-1087.	1.4	62
111	Adolescent and Adult Children of Parents with Parkinson's Disease: Incorporating Their Needs in Clinical Guidelines. <i>Parkinson's Disease</i> , 2011, 2011, 1-6.	0.6	16
112	Corticomotor representation to a human forearm muscle changes following cervical spinal cord injury. <i>European Journal of Neuroscience</i> , 2011, 34, 1839-1846.	1.2	72
113	The mesenchymal stem cells in multiple sclerosis (MSCIMS) trial protocol and baseline cohort characteristics: an open-label pre-test: post-test study with blinded outcome assessments. <i>Trials</i> , 2011, 12, 62.	0.7	104
114	Asymmetric hemispheric representation of perictal heart rate modulation is individually lateralised. <i>Epileptic Disorders</i> , 2011, 13, 172-176.	0.7	11
115	A tool to measure the attributes of receiving IV therapy in a home versus hospital setting: the Multiple Sclerosis Relapse Management Scale (MSRMS). <i>Health and Quality of Life Outcomes</i> , 2011, 9, 80.	1.0	4
116	Diagnostic criteria for multiple sclerosis: 2010 Revisions to the McDonald criteria. <i>Annals of Neurology</i> , 2011, 69, 292-302.	2.8	8,001
117	Disability, atrophy and cortical reorganization following spinal cord injury. <i>Brain</i> , 2011, 134, 1610-1622.	3.7	238
118	Atopic myelitis in a European woman residing in Japan. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2011, 82, 1022-1024.	0.9	6
119	A longitudinal functional MRI study of non-arteritic anterior ischaemic optic neuropathy patients. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2011, 82, 905-913.	0.9	8
120	Dissecting structureâ€“function interactions in acute optic neuritis to investigate neuroplasticity. <i>Human Brain Mapping</i> , 2010, 31, 276-286.	1.9	34
121	Pharmacological management of symptoms in multiple sclerosis: current approaches and future directions. <i>Lancet Neurology</i> , The, 2010, 9, 1182-1199.	4.9	146
122	Increased urinary free immunoglobulin light chain excretion in patients with multiple sclerosis. <i>Journal of Neuroimmunology</i> , 2010, 220, 99-103.	1.1	8
123	Neuroplasticity predicts outcome of optic neuritis independent of tissue damage. <i>Annals of Neurology</i> , 2010, 67, 99-113.	2.8	75
124	Method for simultaneous voxelâ€“based morphometry of the brain and cervical spinal cord area measurements using 3Dâ€“MDEFT. <i>Journal of Magnetic Resonance Imaging</i> , 2010, 32, 1242-1247.	1.9	33
125	T1-relaxation time changes over five years in relapsing-remitting multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2010, 16, 427-433.	1.4	28
126	Scanning Laser Polarimetry Quantification of Retinal Nerve Fiber Layer Thinning Following Optic Neuritis. <i>Journal of Neuro-Ophthalmology</i> , 2010, 30, 235-242.	0.4	9

#	ARTICLE	IF	CITATIONS
127	Lesion enhancement diminishes with time in primary progressive multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2010, 16, 317-324.	1.4	31
128	Assessing Neuronal Metabolism In Vivo by Modeling Imaging Measures. <i>Journal of Neuroscience</i> , 2010, 30, 15030-15033.	1.7	47
129	Early MRI in optic neuritis: the risk for clinically definite multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2010, 16, 156-165.	1.4	62
130	Effect sizes can be misleading: is it time to change the way we measure change?. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2010, 81, 1044-1048.	0.9	43
131	Chronic cerebrospinal venous insufficiency. <i>Multiple Sclerosis Journal</i> , 2010, 16, 770-770.	1.4	5
132	Hippocampal atrophy in relapsing-remitting and primary progressive MS: a comparative study. <i>Multiple Sclerosis Journal</i> , 2010, 16, 1083-1090.	1.4	52
133	Urinary neopterin and nitric oxide metabolites as markers of interferon \hat{I}^2 -1a activity in primary progressive multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2010, 16, 1066-1072.	1.4	20
134	Recovery after spinal cord relapse in multiple sclerosis is predicted by radial diffusivity. <i>Multiple Sclerosis Journal</i> , 2010, 16, 1193-1202.	1.4	63
135	Combining tractography and cortical measures to test system-specific hypotheses in multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2010, 16, 555-565.	1.4	33
136	Refinement and validation of the Parental Illness Impact Scale. <i>Parkinsonism and Related Disorders</i> , 2010, 16, 181-185.	1.1	12
137	Primary progressive multiple sclerosis diagnostic criteria: a reappraisal. <i>Multiple Sclerosis Journal</i> , 2009, 15, 1459-1465.	1.4	35
138	Magnetization transfer ratio abnormalities reflect clinically relevant grey matter damage in multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2009, 15, 668-677.	1.4	41
139	MRI measures show significant cerebellar gray matter volume loss in multiple sclerosis and are associated with cerebellar dysfunction. <i>Multiple Sclerosis Journal</i> , 2009, 15, 811-817.	1.4	76
140	The size of the treatment effect: do patients and proxies agree?. <i>BMC Neurology</i> , 2009, 9, 12.	0.8	7
141	Investigation of white matter pathology in ALS and PLS using tract-based spatial statistics. <i>Human Brain Mapping</i> , 2009, 30, 615-624.	1.9	123
142	Abnormal connectivity of the sensorimotor network in patients with MS: A multicenter fMRI study. <i>Human Brain Mapping</i> , 2009, 30, 2412-2425.	1.9	51
143	Exploring the relationship between white matter and gray matter damage in early primary progressive multiple sclerosis: An in vivo study with TBSS and VBM. <i>Human Brain Mapping</i> , 2009, 30, 2852-2861.	1.9	170
144	Assessing structure and function of the afferent visual pathway in multiple sclerosis and associated optic neuritis. <i>Journal of Neurology</i> , 2009, 256, 305-319.	1.8	94

#	ARTICLE	IF	CITATIONS
145	Improving function: a new treatment era for multiple sclerosis?. <i>Lancet, The</i> , 2009, 373, 697-698.	6.3	10
146	Impairment of movement-associated brain deactivation in multiple sclerosis: further evidence for a functional pathology of interhemispheric neuronal inhibition. <i>Experimental Brain Research</i> , 2008, 187, 25-31.	0.7	52
147	MRI characteristics of atypical idiopathic inflammatory demyelinating lesions of the brain. <i>Journal of Neurology</i> , 2008, 255, 1-10.	1.8	80
148	Longitudinal evaluation of clinically early relapsing-remitting multiple sclerosis with diffusion tensor imaging. <i>Journal of Neurology</i> , 2008, 255, 390-397.	1.8	27
149	A three-year, multi-parametric MRI study in patients at presentation with CIS. <i>Journal of Neurology</i> , 2008, 255, 683-691.	1.8	65
150	Predicting progression in primary progressive multiple sclerosis: A 10-year multicenter study. <i>Annals of Neurology</i> , 2008, 63, 790-793.	2.8	101
151	Gray matter atrophy is related to long-term disability in multiple sclerosis. <i>Annals of Neurology</i> , 2008, 64, 247-254.	2.8	425
152	Relating functional changes during hand movement to clinical parameters in patients with multiple sclerosis in a multi-centre fMRI study. <i>European Journal of Neurology</i> , 2008, 15, 113-122.	1.7	75
153	Longitudinal proxy measurements in multiple sclerosis: patient-proxy agreement on the impact of MS on daily life over a period of two years. <i>BMC Neurology</i> , 2008, 8, 2.	0.8	7
154	MRI in multiple sclerosis: current status and future prospects. <i>Lancet Neurology, The</i> , 2008, 7, 615-625.	4.9	295
155	Diffusion-based tractography in neurological disorders: concepts, applications, and future developments. <i>Lancet Neurology, The</i> , 2008, 7, 715-727.	4.9	360
156	The Cervical Dystonia Impact Profile (CDIP-58): Can a Rasch developed patient reported outcome measure satisfy traditional psychometric criteria?. <i>Health and Quality of Life Outcomes</i> , 2008, 6, 58.	1.0	19
157	Reproducibility of fMRI in the clinical setting: Implications for trial designs. <i>NeuroImage</i> , 2008, 42, 603-610.	2.1	49
158	Developing the ICF Core Sets for multiple sclerosis to specify functioning. <i>Multiple Sclerosis Journal</i> , 2008, 14, 252-254.	1.4	41
159	Large-scale, multicentre, quantitative MRI study of brain and cord damage in primary progressive multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2008, 14, 455-464.	1.4	58
160	Disability and T2 MRI lesions: a 20-year follow-up of patients with relapse onset of multiple sclerosis. <i>Brain</i> , 2008, 131, 808-817.	3.7	783
161	Neutralizing anti-interferon beta antibodies are associated with reduced side effects and delayed impact on efficacy of Interferon-beta. <i>Multiple Sclerosis Journal</i> , 2008, 14, 212-218.	1.4	48
162	The patient's experience of being a human subject. <i>Journal of the Royal Society of Medicine</i> , 2008, 101, 416-422.	1.1	11

#	ARTICLE	IF	CITATIONS
163	Magnetization Transfer Ratio in Gray Matter. <i>Archives of Neurology</i> , 2008, 65, 1454.	4.9	59
164	Neurorehabilitation in Multiple Sclerosis. <i>Topics in Spinal Cord Injury Rehabilitation</i> , 2008, 14, 63-75.	0.8	0
165	Optic nerve magnetization transfer imaging and measures of axonal loss and demyelination in optic neuritis. <i>Multiple Sclerosis Journal</i> , 2007, 13, 875-879.	1.4	47
166	Spinal cord spectroscopy and diffusion-based tractography to assess acute disability in multiple sclerosis. <i>Brain</i> , 2007, 130, 2220-2231.	3.7	154
167	Voxel-based analysis of grey matter magnetization transfer ratio maps in early relapsing remitting multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2007, 13, 483-489.	1.4	44
168	Normal-appearing grey and white matter T1 abnormality in early relapsing-remitting multiple sclerosis: a longitudinal study. <i>Multiple Sclerosis Journal</i> , 2007, 13, 169-177.	1.4	41
169	Normal-Appearing Brain T1 Relaxation Time Predicts Disability in Early Primary Progressive Multiple Sclerosis. <i>Archives of Neurology</i> , 2007, 64, 411.	4.9	71
170	Relationship of triple dose contrast enhanced lesions with clinical measures and brain atrophy in early relapsing-remitting multiple sclerosis: a two-year longitudinal study. <i>Multiple Sclerosis Journal</i> , 2007, 13, 178-185.	1.4	11
171	Localized grey matter damage in early primary progressive multiple sclerosis contributes to disability. <i>NeuroImage</i> , 2007, 37, 253-261.	2.1	99
172	Promises, promises. <i>Annals of Neurology</i> , 2007, 61, 1-2.	2.8	6
173	Evidence-based guidelines for using the Short Form 36 in cervical dystonia. <i>Movement Disorders</i> , 2007, 22, 122-127.	2.2	18
174	Two-dimensional population map of cortical connections in the human internal capsule. <i>Journal of Magnetic Resonance Imaging</i> , 2007, 25, 48-54.	1.9	56
175	The relationship between brain activity and peak grip force is modulated by corticospinal system integrity after subcortical stroke. <i>European Journal of Neuroscience</i> , 2007, 25, 1865-1873.	1.2	136
176	MRI criteria for multiple sclerosis in patients presenting with clinically isolated syndromes: a multicentre retrospective study. <i>Lancet Neurology</i> , The, 2007, 6, 677-686.	4.9	292
177	Rating scales as outcome measures for clinical trials in neurology: problems, solutions, and recommendations. <i>Lancet Neurology</i> , The, 2007, 6, 1094-1105.	4.9	412
178	Optic nerve diffusion tensor imaging in optic neuritis. <i>NeuroImage</i> , 2006, 30, 498-505.	2.1	151
179	Optic nerve atrophy and retinal nerve fibre layer thinning following optic neuritis: Evidence that axonal loss is a substrate of MRI-detected atrophy. <i>NeuroImage</i> , 2006, 31, 286-293.	2.1	176
180	Plasma cerebrosterol and magnetic resonance imaging measures in multiple sclerosis. <i>Clinical Neurology and Neurosurgery</i> , 2006, 108, 456-460.	0.6	35

#	ARTICLE	IF	CITATIONS
181	Functional anatomy of interhemispheric cortical connections in the human brain. <i>Journal of Anatomy</i> , 2006, 209, 311-320.	0.9	192
182	Metabolite changes in early relapsing/remitting multiple sclerosis. <i>Journal of Neurology</i> , 2006, 253, 224-230.	1.8	68
183	Functional response to active and passive ankle movements with clinical correlations in patients with primary progressive multiple sclerosis. <i>Journal of Neurology</i> , 2006, 253, 882-891.	1.8	58
184	Localization of grey matter atrophy in early RRMS. <i>Journal of Neurology</i> , 2006, 253, 1495-1501.	1.8	102
185	Home versus outpatient administration of intravenous steroids for multiple-sclerosis relapses: a randomised controlled trial. <i>Lancet Neurology</i> , The, 2006, 5, 565-571.	4.9	41
186	Upper cervical cord area in early relapsing-remitting multiple sclerosis: Cross-sectional study of factors influencing cord size. <i>Journal of Magnetic Resonance Imaging</i> , 2006, 23, 473-476.	1.9	44
187	Selective magnetization transfer ratio decrease in the visual cortex following optic neuritis. <i>Brain</i> , 2006, 129, 1031-1039.	3.7	88
188	Probabilistic diffusion tractography: a potential tool to assess the rate of disease progression in amyotrophic lateral sclerosis. <i>Brain</i> , 2006, 129, 1859-1871.	3.7	177
189	Longitudinal Changes in Cerebral Response to Proprioceptive Input in Individual Patients after Stroke: An fMRI Study. <i>Neurorehabilitation and Neural Repair</i> , 2006, 20, 398-405.	1.4	60
190	Quantification of optic nerve head topography in optic neuritis: a pilot study. <i>British Journal of Ophthalmology</i> , 2006, 90, 1128-1131.	2.1	25
191	Regional Gray Matter Atrophy in Early Primary Progressive Multiple Sclerosis. <i>Archives of Neurology</i> , 2006, 63, 1175.	4.9	157
192	Motor system activation after subcortical stroke depends on corticospinal system integrity. <i>Brain</i> , 2006, 129, 809-819.	3.7	369
193	The Evolution of Prefrontal Inputs to the Cortico-pontine System: Diffusion Imaging Evidence from Macaque Monkeys and Humans. <i>Cerebral Cortex</i> , 2006, 16, 811-818.	1.6	258
194	Neurorehabilitation in multiple sclerosis: foundations, facts and fiction. <i>Current Opinion in Neurology</i> , 2005, 18, 267-271.	1.8	30
195	Clinically isolated syndromes suggestive of multiple sclerosis, part I: natural history, pathogenesis, diagnosis, and prognosis. <i>Lancet Neurology</i> , The, 2005, 4, 281-288.	4.9	513
196	Clinically isolated syndromes suggestive of multiple sclerosis, part 2: non-conventional MRI, recovery processes, and management. <i>Lancet Neurology</i> , The, 2005, 4, 341-348.	4.9	129
197	Optic radiation changes after optic neuritis detected by tractography-based group mapping. <i>Human Brain Mapping</i> , 2005, 25, 308-316.	1.9	114
198	Adaptive cortical plasticity in higher visual areas after acute optic neuritis. <i>Annals of Neurology</i> , 2005, 57, 622-633.	2.8	100

#	ARTICLE	IF	CITATIONS
199	Retinal nerve fiber layer axonal loss and visual dysfunction in optic neuritis. <i>Annals of Neurology</i> , 2005, 58, 383-391.	2.8	477
200	Diagnostic criteria for multiple sclerosis: 2005 revisions to the "McDonald Criteria". <i>Annals of Neurology</i> , 2005, 58, 840-846.	2.8	4,495
201	Identifying brain regions for integrative sensorimotor processing with ankle movements. <i>Experimental Brain Research</i> , 2005, 166, 31-42.	0.7	132
202	The impact of inpatient neurorehabilitation on psychological well-being on discharge and at 3 month follow-up. <i>Journal of Neurology</i> , 2005, 252, 814-819.	1.8	7
203	Factors influencing work retention for people with multiple sclerosis. <i>Journal of Neurology</i> , 2005, 252, 892-896.	1.8	98
204	Increasing normal-appearing grey and white matter magnetisation transfer ratio abnormality in early relapsing-remitting multiple sclerosis. <i>Journal of Neurology</i> , 2005, 252, 1037-1044.	1.8	72
205	The distribution of magnetic resonance imaging response to interferon-1b in multiple sclerosis. <i>Journal of Neurology</i> , 2005, 252, 1455-1458.	1.8	23
206	Functional-Anatomical Validation and Individual Variation of Diffusion Tractography-based Segmentation of the Human Thalamus. <i>Cerebral Cortex</i> , 2005, 15, 31-39.	1.6	514
207	A longitudinal study of cognition in primary progressive multiple sclerosis. <i>Brain</i> , 2005, 128, 2891-2898.	3.7	99
208	Emergence of thalamic magnetization transfer ratio abnormality in early relapsing-remitting multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2005, 11, 276-281.	1.4	35
209	Grey and white matter volume changes in early primary progressive multiple sclerosis: a longitudinal study. <i>Brain</i> , 2005, 128, 1454-1460.	3.7	135
210	Magnetization transfer histograms in clinically isolated syndromes suggestive of multiple sclerosis. <i>Brain</i> , 2005, 128, 2911-2925.	3.7	101
211	Primary Progressive Multiple Sclerosis. <i>CNS Drugs</i> , 2005, 19, 369-376.	2.7	41
212	Exploring rating scale responsiveness. <i>Neurology</i> , 2004, 62, 1842-1844.	1.5	37
213	Magnetic resonance imaging predictors of disability in primary progressive multiple sclerosis: a 5-year study. <i>Multiple Sclerosis Journal</i> , 2004, 10, 398-401.	1.4	25
214	Estimation of the macromolecular proton fraction and bound pool T2 in multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2004, 10, 607-613.	1.4	45
215	Progressive grey matter atrophy in clinically early relapsing-remitting multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2004, 10, 387-391.	1.4	125
216	Early development of multiple sclerosis is associated with progressive grey matter atrophy in patients presenting with clinically isolated syndromes. <i>Brain</i> , 2004, 127, 1101-1107.	3.7	335

#	ARTICLE	IF	CITATIONS
217	Diffusion tensor imaging of early relapsing-remitting multiple sclerosis with histogram analysis using automated segmentation and brain volume correction. <i>Multiple Sclerosis Journal</i> , 2004, 10, 9-15.	1.4	45
218	Elevated white matter myo-inositol in clinically isolated syndromes suggestive of multiple sclerosis. <i>Brain</i> , 2004, 127, 1361-1369.	3.7	193
219	A serial MRI study following optic nerve mean area in acute optic neuritis. <i>Brain</i> , 2004, 127, 2498-2505.	3.7	125
220	Specificity of Barkhof Criteria in Predicting Conversion to Multiple Sclerosis When Applied to Clinically Isolated Brainstem Syndromes. <i>Archives of Neurology</i> , 2004, 61, 222.	4.9	32
221	Visual recovery following acute optic neuritis. <i>Journal of Neurology</i> , 2004, 251, 996-1005.	1.8	91
222	Patient dissatisfaction: Insights into the rehabilitation process. <i>Journal of Neurology</i> , 2004, 251, 1094-7.	1.8	7
223	European validation of a standardized clinical description of multiple sclerosis. <i>Journal of Neurology</i> , 2004, 251, 1472-1480.	1.8	40
224	The influence of time after stroke on brain activations during a motor task. <i>Annals of Neurology</i> , 2004, 55, 829-834.	2.8	118
225	Patient-based outcomes of cervical dystonia: A review of rating scales. <i>Movement Disorders</i> , 2004, 19, 1054-1059.	2.2	38
226	Overview of primary progressive multiple sclerosis (PPMS): similarities and differences from other forms of MS, diagnostic criteria, pros and cons of progressive diagnosis. <i>Multiple Sclerosis Journal</i> , 2004, 10, S2-S7.	1.4	50
227	Rehabilitation of the Cancer Patient: Experience in a Neurological Unit. <i>Neurorehabilitation and Neural Repair</i> , 2004, 18, 76-79.	1.4	15
228	Functional significance of the ipsilateral hemisphere during movement of the affected hand after stroke. <i>Experimental Neurology</i> , 2004, 190, 425-432.	2.0	103
229	Characterizing function-structure relationships in the human visual system with functional MRI and diffusion tensor imaging. <i>NeuroImage</i> , 2004, 21, 1452-1463.	2.1	149
230	Grey and white matter atrophy in early clinical stages of primary progressive multiple sclerosis. <i>NeuroImage</i> , 2004, 22, 353-359.	2.1	80
231	Serum gelatinase B/MMP-9 in primary progressive multiple sclerosis patients treated with interferon-beta-1a. <i>Journal of Neurology</i> , 2003, 250, 1037-1043.	1.8	14
232	Socio-demographic variables are limited predictors of health status in multiple sclerosis. <i>Journal of Neurology</i> , 2003, 250, 1088-1093.	1.8	9
233	Does neurorehabilitation have a role in relapsing-remitting multiple sclerosis?. <i>Journal of Neurology</i> , 2003, 250, 1214-1218.	1.8	53
234	Magnetic resonance studies of abnormalities in the normal appearing white matter and grey matter in multiple sclerosis. <i>Journal of Neurology</i> , 2003, 250, 1407-1419.	1.8	216

#	ARTICLE	IF	CITATIONS
235	The normal appearing grey matter in primary progressive multiple sclerosis. <i>Journal of Neurology</i> , 2003, 250, 67-74.	1.8	111
236	A study of the mechanisms of normal-appearing white matter damage in multiple sclerosis using diffusion tensor imaging. <i>Journal of Neurology</i> , 2003, 250, 287-292.	1.8	161
237	Effects of a short outpatient rehabilitation treatment on disability of multiple sclerosis patients. <i>Journal of Neurology</i> , 2003, 250, 861-866.	1.8	91
238	Spinal-cord MRI in multiple sclerosis. <i>Lancet Neurology</i> , The, 2003, 2, 555-562.	4.9	213
239	Guidelines for using quantitative magnetization transfer magnetic resonance imaging for monitoring treatment of multiple sclerosis. <i>Journal of Magnetic Resonance Imaging</i> , 2003, 17, 389-397.	1.9	66
240	Application of a B-spline active surface technique to the measurement of cervical cord volume in multiple sclerosis from three-dimensional MR images. <i>Journal of Magnetic Resonance Imaging</i> , 2003, 18, 368-371.	1.9	23
241	New T2 lesions enable an earlier diagnosis of multiple sclerosis in clinically isolated syndromes. <i>Annals of Neurology</i> , 2003, 53, 673-676.	2.8	85
242	Chapter 1 The Diagnosis of Multiple Sclerosis. <i>Blue Books of Practical Neurology</i> , 2003, 27, 1-11.	0.1	1
243	From diffusion tractography to quantitative white matter tract measures: a reproducibility study. <i>NeuroImage</i> , 2003, 18, 348-359.	2.1	219
244	Diffusion tractography based group mapping of major white-matter pathways in the human brain. <i>NeuroImage</i> , 2003, 19, 1545-1555.	2.1	116
245	Cannabinoids inhibit neurodegeneration in models of multiple sclerosis. <i>Brain</i> , 2003, 126, 2191-2202.	3.7	330
246	Cannabinoids for treatment of spasticity and other symptoms related to multiple sclerosis (CAMS) Tj ETQq0 0 0 rgBT/Overlock 10 Tf 50 6.3 729	6.3	729
247	Chapter 22 Treatment of Progressive Multiple Sclerosis. <i>Blue Books of Practical Neurology</i> , 2003, 27, 341-359.	0.1	0
248	Preliminary magnetic resonance study of the macromolecular proton fraction in white matter: a potential marker of myelin?. <i>Multiple Sclerosis Journal</i> , 2003, 9, 246-249.	1.4	32
249	Disability in multiple sclerosis is related to normal appearing brain tissue MTR histogram abnormalities. <i>Multiple Sclerosis Journal</i> , 2003, 9, 566-573.	1.4	82
250	Is multiple sclerosis still a clinical diagnosis?. <i>Neurology</i> , 2003, 61, 596-597.	1.5	8
251	Primary progressive multiple sclerosis: a 5-year clinical and MR study. <i>Brain</i> , 2003, 126, 2528-2536.	3.7	115
252	Serial magnetization transfer imaging in acute optic neuritis. <i>Brain</i> , 2003, 127, 692-700.	3.7	107

#	ARTICLE	IF	CITATIONS
253	Chapter 20 Rehabilitation in Multiple Sclerosis. Blue Books of Practical Neurology, 2003, 27, 317-328.	0.1	0
254	Two-year follow-up study of primary and transitional progressive multiple sclerosis. Multiple Sclerosis Journal, 2002, 8, 108-114.	1.4	43
255	Quality of Life Measurement After Stroke. Stroke, 2002, 33, 1348-1356.	1.0	166
256	A Longitudinal Study of Abnormalities on MRI and Disability from Multiple Sclerosis. New England Journal of Medicine, 2002, 346, 158-164.	13.9	806
257	Developing clinical outcome measures in multiple sclerosis: an evolving process. Multiple Sclerosis Journal, 2002, 8, 357-358.	1.4	8
258	T1 histograms of normal-appearing brain tissue are abnormal in early relapsing-remitting multiple sclerosis. Multiple Sclerosis Journal, 2002, 8, 211-216.	1.4	36
259	Quantitative 1H MRS imaging 14 years after presenting with a clinically isolated syndrome suggestive of multiple sclerosis. Multiple Sclerosis Journal, 2002, 8, 207-210.	1.4	62
260	Measurement of atrophy in multiple sclerosis: pathological basis, methodological aspects and clinical relevance. Brain, 2002, 125, 1676-1695.	3.7	534
261	The diagnosis and management of multiple sclerosis. , 2002, , 1620-1632.		0
262	Progress in neurorehabilitation in multiple sclerosis. Current Opinion in Neurology, 2002, 15, 267-270.	1.8	14
263	Application of the new McDonald criteria to patients with clinically isolated syndromes suggestive of multiple sclerosis. Annals of Neurology, 2002, 52, 47-53.	2.8	251
264	The reproducibility and sensitivity of brain tissue volume measurements derived from an SPM-based segmentation methodology. Journal of Magnetic Resonance Imaging, 2002, 15, 259-267.	1.9	136
265	Disability and lesion load in MS: a reassessment with MS functional composite score and 3D fast FLAIR. Journal of Neurology, 2002, 249, 18-24.	1.8	36
266	Monitoring disease activity and progression in primary progressive multiple sclerosis using MRI: sub-voxel registration to identify lesion changes and to detect cerebral atrophy. Journal of Neurology, 2002, 249, 171-177.	1.8	31
267	The relationship between lesion and normal appearing brain tissue abnormalities in early relapsing remitting multiple sclerosis. Journal of Neurology, 2002, 249, 193-199.	1.8	64
268	The Multiple Sclerosis Impact Scale (MSIS-29): A new patient-based outcome measure. Brain, 2001, 124, 962-973.	3.7	865
269	Preliminary evidence for neuronal damage in cortical grey matter and normal appearing white matter in short duration relapsing-remitting multiple sclerosis: a quantitative MR spectroscopic imaging study. Journal of Neurology, 2001, 248, 131-138.	1.8	136
270	Recommended diagnostic criteria for multiple sclerosis: Guidelines from the international panel on the diagnosis of multiple sclerosis. Annals of Neurology, 2001, 50, 121-127.	2.8	6,122

#	ARTICLE	IF	CITATIONS
271	Diffusion tensor imaging in early relapsing-remitting multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2001, 7, 290-297.	1.4	73
272	The predictive value of gadolinium enhancement for long term disability in relapsingâ remitting multiple sclerosis â preliminary results. <i>Multiple Sclerosis Journal</i> , 2001, 7, 23-25.	1.4	20
273	Quantitative contrast-enhanced magnetic resonance imaging to evaluate blood-brain barrier integrity in multiple sclerosis: a preliminary study. <i>Multiple Sclerosis Journal</i> , 2001, 7, 75-82.	1.4	5
274	A 1H magnetic resonance spectroscopy study of aging in parietal white matter: implications for trials in multiple sclerosis. <i>Magnetic Resonance Imaging</i> , 2000, 18, 455-459.	1.0	71
275	Kurtzke scales revisited: the application of psychometric methods to clinical intuition. <i>Brain</i> , 2000, 123, 1027-1040.	3.7	265
276	Correlates of Executive Function in Multiple Sclerosis:. <i>Journal of Neuropsychiatry and Clinical Neurosciences</i> , 1999, 11, 45-50.	0.9	99
277	Evaluating the role of botulinum toxin type A in adults with focal spasticity. <i>European Journal of Neurology</i> , 1999, 6, s75-s75.	1.7	3
278	Nuclear magnetic resonance monitoring of treatment and prediction of outcome in multiple sclerosis. <i>Philosophical Transactions of the Royal Society B: Biological Sciences</i> , 1999, 354, 1687-1695.	1.8	7
279	Management of spasticity in hereditary spastic paraplegia. <i>Physiotherapy Research International</i> , 1999, 4, 68-76.	0.7	4
280	Integrated care pathways: evaluating inpatient rehabilitation in stroke. <i>International Journal of Therapy and Rehabilitation</i> , 1997, 4, 97-102.	0.1	8
281	Strategies for optimizing MRI techniques aimed at monitoring disease activity in multiple sclerosis treatment trials. <i>Journal of Neurology</i> , 1997, 244, 76-84.	1.8	70
282	Imaging of the spinal cord and brain in multiple sclerosis: a comparative study between fast flair and fast spin echo. <i>Journal of Neurology</i> , 1997, 244, 119-124.	1.8	68
283	Recommendations from the national multiple sclerosis society clinical outcomes assessment task force. <i>Annals of Neurology</i> , 1997, 42, 379-382.	2.8	342
284	Rehabilitation in a neuroscience centre: the role of expert assessment and selection. <i>International Journal of Therapy and Rehabilitation</i> , 1996, 3, 303-308.	0.1	14
285	Macroscopic and microscopic assessments of disease burden by MRI in multiple sclerosis: Relationship to clinical parameters. <i>Journal of Magnetic Resonance Imaging</i> , 1996, 6, 580-584.	1.9	50
286	Clinical outcomes assessment in multiple sclerosis. <i>Annals of Neurology</i> , 1996, 40, 469-479.	2.8	155
287	Patterns of disease activity in multiple sclerosis patients: A study with quantitative gadolinium-enhanced brain MRI and cytokine measurement in different clinical subgroups. <i>Journal of Neurology</i> , 1996, 243, 536-542.	1.8	37
288	A little bit of toxin does you good?. <i>Physiotherapy Research International</i> , 1996, 1, 141-147.	0.7	3

#	ARTICLE	IF	CITATIONS
289	Introduction of integrated care pathways for patients with multiple sclerosis in an inpatient neurorehabilitation setting. Disability and Rehabilitation, 1995, 17, 443-448.	0.9	30
290	Major differences in the dynamics of primary and secondary progressive multiple sclerosis. Annals of Neurology, 1991, 29, 53-62.	2.8	488
291	Multiple Sclerosis and Demyelinating Diseases. , 0, , 411-447.		5
292	Value and limits of rehabilitation in multiple sclerosis. , 0, , 140-151.		0
293	Electrophysiological assessment in multiple sclerosis. , 0, , 112-119.		0
294	The pathophysiology of multiple sclerosis. , 0, , 8-21.		1
295	Treatment for patients with primary progressive multiple sclerosis. , 0, , 604-613.		0
296	Clinical trials to test rehabilitation. , 0, , 157-164.		1
297	Magnetic resonance imaging to assess gray matter damage in multiple sclerosis. , 0, , 86-92.		0
298	Application of functional magnetic resonance imaging in multiple sclerosis. , 0, , 93-102.		0
299	Functional magnetic resonance imaging in focal CNS damage. , 0, , 103-111.		0
300	Functional magnetic resonance imaging monitoring of therapeutic interventions in multiple sclerosis. , 0, , 120-126.		0
301	Prognosis in neurorehabilitation. , 0, , 152-156.		0
302	Back home. , 0, , 230-239.		0